Advanced search
Publication Cover
Expert Review of Anti-infective Therapy Volume 1, 2003 - Issue 4
Submit an article Journal homepage
40
Views
37
CrossRef citations to date
0
Altmetric
Review

Control of influenza virus infection by immunity to conserved viral features

Suzanne L Epstein Laboratory of Immunology and Developmental Biology, Division of Cellular and Gene Therapies, HFM-730, Office of Cellular, Tissue and Gene Therapies, Center for Biologics Evaluation and Research, Food and Drug Administration. [email protected]
Pages 627-638 | Published online: 10 Jan 2014

References

  • Wright PF, Webster RG. Orthomyxoviruses. In: Virology 4th Edition. Knipe DM, Howley PM, Griffin DE, et al (Eds). Lippincott Williams &Wilkins, PA, USA, 1533–1579 (2001)
  • Kilbourne ED. Epidemiology of Influenza. In: The Influenza Viruses and Influenza. Kilbourne ED (Ed). Academic Press, Inc., NY, USA 483–538 (1975)•
  • Updated Recommendations from the Advisory Committee on Immunization Practices in Response to Delays in Supply of Influenza Vaccine for the 2000-01 Season. Mor.MortaLWklyRep. 49, 888–892 (2000).
  • Murphy BR Webster RG. Orthomyxoviruses. In: Wrology 2nd Edition. Fields BN, Knipe DM, Chanock RM, et al (Eds). Raven Press, NY, USA, 1091-1152(1990).
  • de St. Groth SF, Donnelley M. Studies in experimental immunology of influenza. IV The protective value of active immunization. Aust. J. Exp. Bid Med Sci. 28, 61–75 (1950).
  • Liang S, Mozdzanowska K, Palladino G, Gerhard W Heterosubtypic immunity to influenza type A virus in mice: effector mechanisms and their longevity. J. Immurzol 152,1653–1661 (1994).
  • Webster RG. The importance of animal influenza for human disease. Vaccine 20, S16—S20 (2002).
  • Qaas ECJ, Osterhaus ADME, van Beek R, et al Human influenza A H5N1 virus related to a highly pathogenic avian influenza virus. Lancet 351, 472–477(1998).
  • Saito T, Lim W, Suzuki T, et al Characterization of a human H9N2 influenza virus isolated in Hong Kong. Vaccine 20,125–133 (2001).
  • van Kolfichooten E Dutch veterinarian becomes first victim of avian influenza. Lancet 361, 1444, (2003).
  • Schulman JL, Kilbourne ED. Induction of partial specific heterotypic immunity in mice by a single infection with influenza A virus. j Bacterial. 89, 170–174 (1965).
  • Scholtissek C. Genetic relatedness of influenza viruses (RNA and protein). In: Genetics of Influenza Viruses. Palese Kingsbury DW (Eds). Springer-Verlag, NY, USA 99–126 (1983).
  • Altmiiller A, Fitch WM, Scholtissek C Biological and genetic evolution of the nucleoprotein gene of human influenza A viruses.' Gen.Wrol. 70,2111-2119(1989).
  • XU X Cox NJ, Bender CA, Regnery HI, Shaw MW Genetic variation in neuraminidase genes of influenza A (H3N2) viruses. Virology 224,175–183 (1996).
  • Kilbourne ED. Influenza. Plenum Medical Book Co., NY, USA 229–232 (1987).
  • Yetter RA, Lehrer S, Ramphal R, Small PA Jr. Outcome of influenza infection: effect of site of initial infection and heterotypic immunity. Infect. Immun. 29,654–662 (1980)
  • Renegar KB. Influenza virus infections and immunity: a review of human and animal models. Lab. Azzim. Sci. 42,222–232 (1992).
  • Ada GL, Jones PD. The immune response to influenza infection. Curr. Top. Microbial Immund 128,1–54 (1986).
  • De Jong JC, Beyer WEP, Palache AM, Rimmelzwaan GE Osterhaus ADME: Mismatch between the 1997/1998 influenza vaccine and the major epidemic A(H3N2) virus strain as the cause of an inadequate vaccine-induced antibody response to this strain in the elderly./ Med. Viral 61, 94–99 (2000)
  • Wells MA, Albrecht P Ennis FA. Recovery from a viral respiratory infection. I. Influenza pneumonia in normal and T-deficient mice./ Immurzol 126, 1036–1041 (1981).
  • Doherty PC, Topham DJ, Tripp RA, Cardin RD, Brooks JW Stevenson PG. Effector CD4(+) and CD8(+) T-cell mechanisms in the control of respiratory virus infections. Immunot Rev. 159, 105–117 (1997).
  • Lu LY, Askonas BA. Cross-reactivity for different type A influenza viruses of a cloned T-killer cell line. Nature 288, 164–165(1980).
  • Yewdell JW, Bennink JR, Smith GL, Moss B. Influenza A virus nucleoprotein is a major target antigen for cross-reactive anti-influenza A virus cytotoxic T-lymphocytes. Proc. Nad Acad Sci. USA 82,1785–1789 (1985).
  • Webster RG, KawaokaY, Taylor J, Weinberg R, Paoletti E. Efficacy of nudeoprotein and haemagglutinin antigens expressed in fowlpox virus as vaccine for influenza in chickens. Vaccine 9, 303–308(1991).
  • Lawson CM, Bennink JR, Restifo NP, Yewdell JW, Murphy BR Primary pulmonary cytotoxic T-lymphocytes induced by immunization with a vaccinia virus recombinant expressing influenza A virus nucleoprotein peptide do not protect mice against challenge./ Viral 68, 3505–3511 (1994).
  • Ulmer JB, Donnelly JJ, Parker SE, et al Heterologous protection against influenza by injection of DNA encoding a viral protein. Science 259, 1745–1749 (1993).
  • Fu TM, Guan LM, Friedman A, et al Dose-dependence of CIL precursor frequency induced by a DNA vac cine and correlation with protective immunity against influenza virus challenge. j Immunol. 162, 4163–4170 (1999).
  • Taylor SF, Bender BS. 32-microglobulin-deficient mice demonstrate class II MI-IC restricted antiviral CD4+ but not CD8+ CIL against influenza-sensitized autologous splenocytes. Immund Lett. 46, 67–73 (1995).
  • Lukacher AE, Braciale VL, Braciale TJ. In vivo effector function of influenza virus-specific cytotoxic T-lymphocyte clones is highly specific./ E. Med. 160, 814–826 (1984).
  • Topham DJ, Tripp RA, Doherty PC. CD8+ T-cells clear influenza virus by perforin or Fas dependent processes. Immunol. 159, 5197–5200 (1997).
  • Liu AN, Mohammed AZ, Rice WR, et al. Perforin-independent CD8+ T-cell-mediated cytotoxicity of alveolar epithelial cells is preferentially mediated by tumor necrosis factor-a. Relative insensitivity to Fas ligand. Am. J. Respiratory Cell Mot Biol. 20, 849–858 (1999).
  • Zhao MQ, Amir MK, Rice WR, Enelow RI. Type II pneumocyte-CD8+T-cell interactions — relationship between target cell cytotoxicity and activation. Am. J.Respir. Cell Mot Biol. 25, 362–369 (2001).
  • Bender BS, Bell WE, Taylor S, Small PA Jr. Class I major histocompatibility complex-restricted cytotoxic T-lymphocytes are not necessary for heterotypic immunity to influenza. J. Infect. Dis. 170, 1195–1200 (1994).
  • Epstein SL, Lo C-Y, Misplon JA, et al Mechanisms of heterosubtypic immunity to lethal influenza A virus infection in immunocompetent, T-cell-depleted, microglobulin-deficient and J chain-deficient mice. J. Immunol. 158, 1222–1230 (1997).
  • Raulet DH. MHC class I-deficient mice. Adv. Immunol. 55, 381–421 (1994).
  • Epstein SL, Stack A, Misplon JA, et al. Vaccination with DNA encoding internal Proteins of influenza virus does not require CD8+ CI L: Either CD4+ or CD8+ T-cells can promote survival and recovery after challenge. Intl Immunol. 12, 91–101 (2000).
  • Nguyen III I, van Ginkel FW, Vu HL, McGhee JR, Mestecky J. Heterosubtypic immunity to influenza A virus infection requires B-cells but not CD8+ cytotoxic T-lymphocytes.j Infect. Dis. 183, 368–376 (2001).
  • Bot A, Reichlin A, Isobe H, et al Cellular mechanisms involved in protection and recovery from influenza virus infection in immunodeficient mice. J. Wrol. 70, 5668–5672 (1996).
  • Topham DJ, Doherty PC Clearance of an influenza A virus by CD4+ T-cells is inefficient in the absence of B-cells.j Wrol. 72, 882–885 (1998).
  • Epstein SL, Lo GY, Misplon JA, BenninkJR Mechanism of protective immunity against influenza virus infection in mice without antibodies./ Immunol 160, 322–327(1998).
  • Graham MB, Braciale TJ. Resistance to and recovery from lethal influenza virus infection in B-lymphocyte-deficient mice. J. Exp. Med. 186, 2063–2068 (1997).
  • Benton KA, MisplonJA, In GY, Brutkiewicz RR, Prasad SA, Epstein SL Heterosubtypic immunity to influenzaA virus in mice lacking either IgA, all Ig, NKT cells, or y8 T-cells. Immund 166, 7437–7445 (2001).
  • Elkins KL, Bosio CM, Rhinehart-Jones TR. Importance of B-cells but not specific antibodies, in primary and secondaty protective immunity to the intracellular bacterium Francisella tularensis live vaccine strain. Infict. Immu,. 67, 6002–6007 (1999).
  • Mozdzanowska K, Maiese K, Gerhatd W The cell-deficient mice control influenza virus infection more efli-Ltively than Th-and B-cell-deficient mice. Evidence for a Th-independent contribution by B-cells to virus clearance./ Immunol. 164, 2635–2643 (2000).
  • •B cells as APC in the flu system.
  • Mbawuike IN, Six HR, Cate TR, Couch RB. Vaccination with inactivated influenza A virus during pregnancy protects neonatal mice against lethal challenge by influenza A viruses representing three subtypes./ Viral. 64, 1370–1374 (1990).
  • Renegar KB, Small PA. Passive transfer of loeal immunity to influenza virus infection by IgA antibody./ Immund 146, 1972–1978 (1991).
  • Mazanec MB, Kaetzel CS, Lamm ME, Fletcher D, Nedrud JG. Intracellular neutralization of virus by immunoglobulin A antibodies. Proc. Natl Acad. Sci. USA 89, 6901–6905 (1992).
  • Mazanec MB, Coudret CL, Fletcher DR. Intracellular neutralization of influenza virus by immunoglobulin A anti-hemagglutinin monoclonal antibodies. J. Viral. 69, 1339–1343 (1995)•
  • Burns JW, Siadat-Pajouh M, Krishnaney AA, Greenberg HB. Protective effect of rotavirus VP6-specific IgA monoclonal antibodies that lack neutralizing activity. Science 272, 104–107 (1996).
  • Schwartz-Cornil I, Benureau Y, Greenberg H, Hendrickson BA, Cohen J. Heterologous protection induced by the inner capsid proteins of rotavirus requires transcytosis of mucosal immunoglobulins. I Viral. 76, 8110–8117 (2002).
  • Harriman GR, Bogue M, Rogers P, et al. Targeted deletion of the IgA constant region in mice leads to IgA deficiency with alterations in expression of other Ig isotypes. I Immunol. 162, 2521–2529 (1999).
  • Mbawuike IN, Pacheco S, Acuna CL, Switzer KC, Zhang Y, Harriman GR. Mucosal immunity to influenza without IgA: an IgA knockout mouse model. J. Immunol. 162, 2530–2537 (1999).
  • Nguyen HH, Moldoveanu Z, Novak MJ, et al. Heterosubtypic immunity to lethal influenza A virus infection is associated with virus-specific CD8+ cytotoxic T-lymphocyte responses induced in mucosa-associated tissues. Virology 254, 50–60 (1999).
  • ••Emphasizes the importance of anatomicsite in determining whether an immunization induces broad cross-protection.
  • Treanor JJ, Wilkinson BE, Masseoud F, et al. Safety and immunogenicity of a recombinant hemagglutinin vaccine for H5 influenza in humans. Vaccine 19, 1732–1737 (2001).
  • Nicholson KG, Colegate AE, Podda A, et al. Safety and antigenicity of non-adjuvanted and MF59-adjuvanted influenza A/Duck/Singapore/97 (H5N3) vaccine: a randomised trial of two potential vaccines against H5N1 influenza. Lancet 357, 1937–1943 (2001).
  • Suarez DL, Perdue ML, Cox N, et al Comparisons of highly virulent H5N1 influenza A viruses isolated from humans and chickens from Hong Kong./ Viral 72, 6678–6688 (1998).
  • Subbarao K, Krimov A, Katz J, et al Characterization of an avian influenza A (H5N1) virus isolated fipm a child with a fatal respiratory illness. Science 279, 393–396 (1998).
  • Gao P, Watanabe S, Ito T, et al Biologicalheterogeneity, including systemic replication in mice, of H5N1 influenza A virus isolates from humans in Hong Kong. Wrol. 73, 3184–3189 (1999).
  • LOCH Tumpey TM, Morken T, Zaki SR, Cox NJ, KatzJM. A mouse model for the evaluation of pathogenesis and immunity to influenza A (H5N1) viruses isolated from humans./ Viral 73, 5903–5911 (1999).
  • Mbawuike IN, Dillon SB, Demuth SG, Jones CS, Cate TR, Couch RB. Influenza A subtype cross-protection after immunization of outbred mice with a purified chimeric NS1/HA2 influenza virus protein. Vaccine 12, 1340–1349 (1994).
  • Slepushkin VA, Katz JM, Black RA, Gamble WC, Rota PA, Cox NJ. Protection of mice against influenzaA virus challenge by vaccination with baculovirus-expressed M2 protein. Vaccine 13, 1399–1402 (1995).
  • Neirynck S, Deroo T, Saelens X Vanlandschoot P. Jou WM, Fiers W A universal influenza A vaccine based on the extracellular domain of the M2 protein. Nature Med. 5, 1157–1163 (1999).
  • •Cross-protection induced by a protein and mediated by antibodies.
  • Rhodes GH, Dwarki VJ, Abai AM, et al Injection of expression vectors containing viral genes induces cellular, humoral and protective immunity. In: Vaccines. Chanock RM, Brown F, Ginsberg HS, Norrby E (Eds). Cold Spring Harbor Laboratory Press, NY, USA 137–141 (1993).
  • Ulmer JB, Fu T-M, Deck RR, et al Protective CD4+ and CD8+ T-cells against influenza virus induced by vaccination with nucleoprotein DNA. J. Viral 72, 5648–5653 (1998).
  • Kodihalli S, Kobasa DL, Webster RG. Strategies for inducing protection against avian influenza A virus subtypes with DNA vaccines. Vaccine 18, 2592–2599 (2000).
  • Epstein SL, Tumpey TM, Misplon JA, et al DNA vaccine expressing conserved influenza virus proteins protective against H5N1 challenge infection in mice. Emerging Infect. Dis. 8, 796–801 (2002).
  • •Example of protection against potential pandemic subtype by DNA vaccination to conserved antigens.
  • Webster RG, Askonas BA. Cross-protection and cross-reactive cytotoxic T-cells induced by influenza virus vaccines in mice. Eur. Immunol. 10, 396–401 (1980).
  • Takada A, Kuboki N, Okazaki K, et al Avirulent avian influenza virus as a vaccine strain against a potential human pandemic. J. Viral 73, 8303–8307 (1999).
  • ••Demonstrate the possibility of usingexisting inactivated vaccines by a new route of immunization to induce broad cross-protection.
  • Tumpey TM, Renshaw M, Clements JD, Katz JM. Mucosal delivery of inactivated influenza vaccine induces B-cell-dependent heterosubtypic cross-protection against lethal influenza a H5N1 virus infection. J. Viral 75, 5141–5150 (2001).
  • ••Demonstrate the possibility of usingexisting inactivated vaccines by a new route of immunization to induce broad cross-protection.
  • Takada A, Matsushita S, Ninomiya A, Kawaoka Y, Kida H. Intranasal immunization with formalin-inactivated virus vaccine induces a broad spectrum of heterosubtypic immunity against influenza A virus infection in mice. Vaccine 21, 3212–3218 (2003).
  • ••Demonstrate the possibility of usingexisting inactivated vaccines by a new route of immunization to induce broad cross-protection.
  • Morein B, Sundquist B, Hoglund S, Dalsgaard K, Osterhaus A. Iscom, a novel structure for antigenic presentation of membrane proteins from enveloped viruses. Nature 308, 457–460 (1984).
  • Sambhara S, Kurichh A, Miranda R, et al. Heterosubtypic immunity against human influenza A viruses, including recently emerged avian H5 and H9 viruses, induced by FLU-ISCOM vaccine in mice requires both cytotoxic T-lymphocyte and macrophage function. Cell. Immunol. 211, 143–153 (2001).
  • Rimmelzwaan GF, Baars M, van Amerongen G, van Beek R, Osterhaus AE. A single dose of an ISCOM influenza vaccine induces long-lasting protective immunity against homologous challenge infection but fails to protect Cynomolgus macaques against distant drift variants of influenza A (H3N2) viruses. Vaccine 20, 158–163 (2001).
  • Chen HE, Subbarao K, Swayne D, et al. Generation and evaluation of a high-growth reassortant H9N2 influenza A virus as a pandemic vaccine candidate. Vaccine 21, 1974–1979 (2003).
  • Subbarao K, Chen HE, Swayne D, et al. Evaluation of a genetically modified reassortant H5N1 influenza A virus vaccine candidate generated by plasmid-based reverse genetics. Virology 305, 192–200 (2003).
  • Hatta M, Gao P. Halfmann P. Kawaoka Y. Molecular basis for high virulence of Hong Kong H5N1 influenza A viruses. Science 293, 1840–1842 (2001).
  • Murphy BR, Coelingh K. Principles underlying the development and use of live attenuated cold-adapted influenza A and B virus vaccines. Viral Immunology 15, 295–323 (2002).
  • Sonoguchi T, Naito H, Hara M, Takeuchi Y, Fukumi H. Cross-subtype protection in humans during sequential overlapping and/or concurrent epidemics caused by H3N2 and H1N1 influenza viruses./ Infect. Dis. 151, 81–88 (1985).
  • McMichael AJ, Gotch FM, Noble GR, Beare PAS. Cytotoxic T-cell immunity to influenza. N Engl. J. Med. 309, 13–17 (1983).
  • McMichael AJ, Dongworth DW, Gotch FM, Clark A, Potter CW. Declining T-ull immunity to influenza, 1977-1982. Lancet 2, 762–764 (1983).
  • Slepushkin AN. The effect of a previous, attack of Al influenza on susceptibility to A2 virus during the 1957 outbreak. Bull Wld Hlth Org. 20, 297–301 (1959).
  • Jordan WS Jr, Denny FW Jr, Badger GF, et al A study of illness in a group of Cleveland families. XVII. The occurrence of Asian influenza. Am. J. Hyg. 68, 190–212 (1958).
  • Jameson J, Cruz J, Ennis FA. Human cytotoxic T-lymphocyte repertoire to influenza A viruses. J. Viral 72, 8682–8689 (1998).
  • Couch RB, Keitel WA, Cate TR. Improvement of inactivated influenza virus vaccines. J. Infect. Dis. 176\(Suppl. 1), S38—S44 (1997).
  • Ennis FA, Cruz J, Jameson J, Mein M, Burt D, Thipphawong J. Augmentation of human influenza A virus-specific cytotoxic T-lymphocyte memory by influenza vaccine and adjuvanted carriers (ISCOMS). Virology 259, 256–261 (1999).
  • Steinhoff MC, Fries LF, Karron RA,Clements ML, Murphy BR Effect of heterosubtypic immunity on infection with attenuated influenza-A virus vaccines in young children. Clin. Microbial. 31, 836–838 (1993).
  • Glezen WE, Six HR, Perrotta DM, Decker M, Joseph S. Epidemics and their Causative Viruses — Com unity Experience. In: The Molecular Virology and Epidemiology of Influenza. Stuart-Harris CH, Potter CW (Eds). Academic Press, London, UK 17–32 (1984).
  • Selin LK, Nahill SR, Welsh RM. Cross-reactivities in memory cytotoxic T-lymphocyte recognition ofheterologous viruses./ Exp. Med 179, 1933–1943 (1994).

Websites

  • WHO. Influenza pandemic preparedness plan. The role of WHO and guidelines for national or regional planning. World Health Organization. Geneva, Switzerland (1999).
  • WHO Weekly Epidemiological Record. Preparing for the next influenza season in a world altered by SARS. Disease Outbreak #1Severe Acute Respiratory Syndrome, Update 94 www item #20.7-3–2003.
  • www.snm.ch/public/sante/prevention/prev ention_sommaire.htm.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.